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ABSTRACT 
 
Purpose 
The long-term outcome of platinum-induced nephrotoxicity is unknown. This prospective 
single centre longitudinal cohort study evaluated long-term changes following treatment 
in childhood. 
Methods 
63 children treated with platinum (27 cisplatin, 24 carboplatin, 12 both) were studied at 
end of treatment (End), 1 and 10 years later. No child received ifosfamide. Glomerular 
filtration rate (GFR), serum calcium and magnesium (Mg) were measured, and total 
nephrotoxicity score (Ns) graded. 
Results 
There was no significant overall change in renal function over time in any treatment 
group (cisplatin, carboplatin, or combined). Apart from marginally reduced median GFR 
(84 ml/min/1.73m2) and Mg (0.68 mmol/l) at End of cisplatin, median GFR, Ca and Mg 
were normal at all times in each group. At 10 years, GFR was <60 ml/min/1.73m2 in 
11%, Ns grade severe in 15% and oral Mg supplements required in 7% cisplatin patients. 
After cisplatin, older age at treatment was correlated with lower GFR at 10 years 
(p=0.005), and higher Ns at End and 10 years (both p=0.02). After carboplatin, older age 
was associated with lower GFR at all times, and higher Ns at End and 1 year (all p<0.03). 
Higher cisplatin dose rate (>40 mg/m2/day) was associated with higher Ns at 1 year 
(p=0.02) and higher carboplatin dose with lower Mg at 1 year and higher Ns at 1 and 10 
years (all p<0.008). 
Conclusions 
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Platinum nephrotoxicity did not change significantly over 10 years. Its severity was 
correlated to older age at treatment, and at some timepoints to higher cisplatin dose rate 
and higher cumulative carboplatin dose. 
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INTRODUCTION 
The attainment of long-term survival in about 75% of children presenting with 
malignancy in the 1990s1 has been achieved only at the cost of late and chronic toxicity in 
some survivors. Cure has been the paramount aim in most poor and many average 
prognosis malignancies, overruling concerns about chronic toxicity. However, the 
development of late adverse effects of treatment is an increasingly important issue now 
that 1 in 715 young adults in developed countries is a long-term survivor of malignancy.2 
Therefore, in view of the success of contemporary treatment, the philosophy of 
management in good prognosis malignancies is now to cure whilst minimising late 
toxicity.3 
This trend is illustrated by developments in the use of platinum drugs. Cisplatin is 
highly effective and has an important role in the treatment of children with 
neuroblastoma, osteosarcoma and some brain tumours, but chronic ototoxicity, 
neurotoxicity and especially nephrotoxicity4 have encouraged the development of several 
less toxic platinum analogues, principally carboplatin. Although it has a subtly different 
therapeutic profile, carboplatin has been introduced successfully into some protocols for 
germ cell tumours (GCTs), neuroblastoma and certain brain tumours.5,6 Carboplatin 
nephrotoxicity appears less frequent and severe than that due to cisplatin.7 
It is extremely important that long-term nephrotoxicity is documented to inform 
the future development of effective but safer treatments. However, there is very little 
published information about renal function more than three years after completion of 
platinum chemotherapy, and no very long-term longitudinal data. 
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The main aim of this prospective longitudinal single centre cohort study was to 
document changes in renal toxicity over 10 years after completion of cisplatin or 
carboplatin treatment (or both) in children. An additional aim was to determine risk 
factors for long-term nephrotoxicity. 
 
PATIENTS AND METHODS 
Patients and treatment 
68 children and adolescents (<18 years age at treatment) commencing platinum treatment 
in Newcastle between 1981 and 1996 survived at least 10 years after treatment 
completion. Three patients were lost to follow-up (two treated with cisplatin, one with 
carboplatin), one treated with cisplatin declined investigation and one treated with 
carboplatin moved out of the region; however, follow-up by the Northern Region Young 
Persons’ Malignant Disease Registry confirmed that all five were alive 10 years post-
treatment. The other 63 survivors were studied; 27 received cisplatin only, 24 carboplatin 
only, and 12 both. No patient commencing platinum treatment during 1981-1996 died 
from nephrotoxicity. Table 1 shows further patient and treatment characteristics. One 
child had a reduced glomerular filtration rate (GFR) (42 ml/min/1.73m2) prior to cisplatin 
treatment due to pre-renal glomerular impairment at presentation of malignancy, one 
underwent unilateral nephrectomy before receiving carboplatin, and another had renal 
invasion by neuroblastoma before combined platinum treatment. No other patient had 
significant renal dysfunction (raised serum creatinine or GFR <60 ml/min/1.73m2), 
radiological evidence of urinary tract obstruction or renal involvement prior to platinum 
treatment. 
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Several cisplatin administration schedules were employed, all incorporating 
intravenous hyperhydration. The cisplatin dose was 60-200 mg/m2/course, given as a 
continuous infusion (40-100 mg/m2/day) over 1-5 days, except in the four survivors with 
GCTs (given over 20 minutes), and one with osteosarcoma (120 mg/m2 over 1 hour). 
Neuroblastoma and brain tumour protocols employed a cisplatin dose rate of 40 
mg/m2/day (15 children), whilst those for osteosarcoma, GCTs and hepatic tumours 
utilised higher rates (>40-120 mg/m2/day, 24 children). All high dose (200 mg/m2) 
cisplatin courses were given over 5 days at 40 mg/m2/day. 
The carboplatin dose was 300-1200 mg/m2/course. Carboplatin was given on one 
day only except in 6 children with brain tumours who received two doses (500-600 
mg/m2/dose) per course, on consecutive days. Each dose was given over one hour, 
without hyperhydration. Six children with neuroblastoma received high-dose carboplatin 
(1000 mg/m2) prior to autologous bone marrow transplantation. 
High-dose melphalan (180-200 mg/m2) was given prior to autologous bone 
marrow transplantation in nine children with neuroblastoma, including the six also 
receiving high-dose carboplatin. Eight patients also received intravenous intermediate (1 
g/m2) or high (8 g/m2) dose methotrexate. Other chemotherapy received included 
actinomycin D, bleomycin, cyclophosphamide, doxorubicin, etoposide, 5-fluorouracil, 
teniposide and vincristine. No child received ifosfamide. Treatment courses were 
repeated every three weeks except in 13 children on rapid scheduling protocols with 
chemotherapy every 10-14 days. Supportive care protocols included aminoglycosides 
(with therapeutic level monitoring) and amphotericin. 
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A small area of kidney was included in the radiotherapy fields in three children, or 
received a small amount of scatter in a further five. All these children received 
carboplatin only. No child developed haemolytic uraemic syndrome (HUS). 
Assessment of renal function 
Renal function was investigated approximately one month (End), one and 10 years after 
completion of platinum. Glomerular (GFR) and proximal tubular function (serum calcium 
[Ca] and magnesium [Mg] concentrations) were assessed, and nephrotoxicity grading 
(Table 2) calculated, using a standardised protocol.8,9 Age-related reference ranges were 
used. Since it is difficult to perform creatinine clearance measurements accurately in 
children, GFR was calculated from 51Cr-labelled ethylenediaminetetraacetic acid (51Cr-
EDTA) plasma clearance,10 which gives a more accurate value than calculated GFR.11 
Significant adverse clinical consequences of chronic nephrotoxicity (GFR <60 
ml/min/1.73m2, tetany, convulsions, cardiac arrhythmias or hypertension) were recorded 
using standard definitions,8,12 and ongoing treatment with electrolyte supplements 
documented, at each timepoint. 
The study protocol was approved by the Joint Ethics Committee of Newcastle 
Health Authority and the University of Newcastle. Informed consent was obtained from 
the parents and, where appropriate, the patient. 
Statistics 
For analysis of changes with time, the results of renal function investigations were 
expressed both as raw values and categorised as either normal or abnormal (ie below the 
age-related reference range). “No” or “mild” nephrotoxicity (Ns 0-1) was categorised as a 
normal Ns, and “moderate” or “severe” nephrotoxicity (Ns≥2) as abnormal. Changes 
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between End and 1 year, End and 10 years, and 1 and 10 yrs were analysed by the 
Wilcoxon sign rank test (paired raw values) and McNemar’s test for paired proportions 
(percentages of normal and abnormal results, and the presence or absence of a severe 
nephrotoxicity score (Ns≥4), clinically significant complications, or ongoing 
supplementary treatment). Statements describing percentages (and changes in 
percentages) of normal or abnormal results apply to paired data only. 
Analysis of platinum dose as a risk factor for the development of nephrotoxicity at 
each timepoint was performed using linear regression (cumulative dose) and the unpaired 
t-test (cisplatin dose intensity, comparing 40 with >40 mg/m2/day). The outcome 
measures were GFR, Ca, Mg, and Ns. Linear regression was used to evaluate age at 
treatment as a risk factor for GFR, Ca and Ns. However, since the lower limit of the 
reference range of Mg is age-related, and the calculation of Ns incorporates Mg, the mean 
ages of those survivors with normal and those with abnormal results for these variables 
was compared using unpaired t-tests. Risk factor analysis was not performed for the 
combined cisplatin and carboplatin group due to small numbers. 
 
RESULTS 
The 1 and 10 year post-treatment studies were performed at a median (range) of 1.1 (0.7-
2.3) and 10.3 (9.0-12.3) years, respectively, after chemotherapy completion. The timing 
did not differ between the cisplatin, carboplatin and combined groups. Table 3 
summarises the results of renal function investigations and the percentages of normal 
results at End, 1 and 10 years. 
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Substantial inter-individual variability was observed with some survivors showing 
improvement and others deterioration in glomerular, tubular or overall renal function 
during follow-up (Figure 1). However, there was no significant change with time in any 
of the measures of nephrotoxicity in any treatment group, nor in the proportion with 
clinically significant complications or ongoing treatment with supplements. 
Cisplatin alone 
Median GFR and Mg were both slightly reduced at End (84 ml/min/1.73m2 and 0.68 
mmol/l, respectively), but normal at 1 and 10 years. Median Ca was normal at all 
timepoints. Moderate nephrotoxicity was present in 6 (29%), 7 (32%) and 6 (22%), and 
severe nephrotoxicity in 3 (14%), 1 (5%) and 4 (15%) evaluable survivors at End, 1 and 
10 years. 
GFR was <90 and <60 ml/min/1.73m2, respectively, in 12 (60%) and 4 (20%) 
evaluable survivors at End, 9 (43%) and 1 (4%) at 1 year, and 13 (48%) and 3 (11%) at 
10 years. Tetany was documented in 1 (4%) patient at each timepoint. No patient 
experienced a convulsion related to cisplatin-induced hypomagnesaemia or 
hypocalcaemia, but 1 (4%) patient had suffered a serious cardiac arrhythmia due to 
hypomagnesaemia shortly before End. Six (22%), 2 (7%) and 2 (7%) survivors were 
receiving magnesium supplements at End, 1 and 10 years post-treatment, respectively. 
One (4%) patient had stage 1 hypertension at 10 years, but none was on antihypertensive 
medication. 
Older age at treatment was correlated with lower GFR at 10 years (p=0.005) 
(Figure 2a) and greater overall nephrotoxicity measured by higher Ns at End and 10 years 
(both p=0.02), whilst the mean age of children with abnormal Mg at End (10.9 years) and 
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Ns at 10 years (11.0 years) was higher than those with normal values (4.8 years for Mg at 
End, p=0.006; 6.0 years for Ns at 10 years, p=0.01). An increase of 5 years in age at 
treatment was associated with a fall in GFR (measured at 10 years post-treatment) of 13.0 
(95% confidence intervals 4.5-21.5) ml/min/1.73m2. No relationship was seen between 
dose and the severity of toxicity, but higher dose rate was associated with higher Ns at 1 
year (p=0.02). 
Carboplatin alone 
Median GFR, Ca and Mg were all normal at all timepoints. Of evaluable survivors, 
moderate nephrotoxicity was present in 1 (5%) at each timepoint, whilst severe 
nephrotoxicity was present in 1 (5%) at End only. 
GFR was <90 ml/min/1.73m2 in 4 (19%) evaluable survivors at End and at 1 year, 
and 5 (21%) at 10 years. No patient had a GFR <60 ml/min/1.73m2 at any timepoint, and 
none experienced tetany, convulsions or cardiac arrhythmia. Two (8%) and one (4%) 
survivors were receiving magnesium supplements at End and 1 year, respectively, whilst 
one (4%) was taking calcium supplements at 10 years. No patient was hypertensive or on 
antihypertensive medication. 
Older age at treatment was correlated with lower GFR at End, 1 and 10 years 
(p=0.018, p=0.025 and p=0.011, respectively) (Figure 2b) and greater overall 
nephrotoxicity measured by higher Ns at End and 1 year (p=0.001 and p=0.01, 
respectively). In addition, the mean age of children with an abnormal Mg at End (11.4 
years) was higher than that of those with a normal value (4.2 years, p=0.008). An increase 
of 5 years in age was associated with falls in GFR of 17.5 (3-5-31.5) when measured at 
End and of 13.8 (3.3-24.3) ml/min/1.73m2 at 10 years. Higher cumulative carboplatin 
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dose was correlated with lower Mg at 1 year (p=0.001) and higher Ns at 1 and 10 years 
(p=0.008 and p=0.003, respectively). It was also correlated to lower Mg at End (p=0.037), 
but the magnitude of this effect was very small with an increase of 600 mg/m2 leading to 
fall of only 0.015 (0.001-0.029) mmol/l.  
Cisplatin and carboplatin 
Median GFR, Ca and Mg were all normal at each timepoint. Moderate nephrotoxicity was 
present in 2 (18%), 1 (8%) and 1 (8%) evaluable survivors at End, 1 and 10 years, whilst 
no patient had severe nephrotoxicity at any timepoint.  
GFR was <90 and <60 ml/min/1.73m2, respectively, in 5 (50%) and 1 (10%) 
evaluable survivors at End, 4 (33%) and 1 (10%) at 1 year, and 5 (45%) and none at 10 
years. GFR was <60 ml/min/1.73m2 in 1 (10%) evaluable survivor at End and 1 year, but 
in none at 10 years. No patient experienced tetany, convulsions or cardiac arrhythmia. 
One (8%) child was receiving potassium supplements at End, but no patient subsequently 
required supplement treatment. One patient (8%) each had stage 1 and stage 2 
hypertension at 10 years, but none was on antihypertensive medication. 
 
DISCUSSION 
Glomerular or renal tubular toxicity, or both, occur in many children and adolescents 
treated with cisplatin.4,8,13,14 The frequency of nephrotoxicity reported within three years 
of treatment completion has varied widely, probably due to differences in chemotherapy 
schedules and doses, and in timing and methodology of investigation. Nevertheless, a 
very consistent pattern of toxicity has been observed. A fall in GFR has been reported in 
20-80% of children,4,8,13 and may occasionally lead to chronic renal failure (CRF).15 
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Hypomagnesaemia, the commonest feature of chronic proximal tubular toxicity,16 occurs 
in 12-100% of children8,13,14,17 due to impaired tubular magnesium reabsorption, and may 
cause paraesthesiae, tremor, tetany, convulsions and cardiac arrhythmias.18 Less common 
features of cisplatin nephrotoxicity include hypokalaemic metabolic alkalosis,19 
hypocalcaemia (probably secondary to hypomagnesaemia),20 hypertension (probably 
renovascular)21 and rarely HUS.22 Carboplatin nephrotoxicity is similar in nature but 
occurs less frequently and is usually much less severe than that after cisplatin. Mild 
glomerular impairment and hypomagnesaemia have each been reported in 0-25% of 
children.7,23-25 Rarely, carboplatin may lead to CRF, usually in the context of high-dose 
conditioning chemotherapy in heavily pre-treated children undergoing autologous stem 
cell transplantation.26 
There is very little information about the very long-term outcome of platinum 
nephrotoxicity and in particular about changes in severity with time. The Late Effects 
Surveillance System found that Mg increased slightly during the first year but then 
remained unchanged 1-3 years post-treatment.17 Three short-term longitudinal studies 
have reported persistent platinum nephrotoxicity in up to 40% survivors at a median of 
about 2 years after completion of treatment, whilst case reports have described 
persistence of toxicity up to 20 years post-treatment.7,8,13,19 Bergeron did not observe 
significant reductions in Mg or calculated GFR in 30 infants with neuroblastoma 
investigated 4.5-9 years after carboplatin,25 but GFR was assessed indirectly and the 
cumulative carboplatin dose was much lower than in this study.  
Although it is likely that long-term retention of platinum in the kidney and 
involvement of renal tubular cells in platinum excretion are both important in the 
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development of nephrotoxicity, detailed understanding of the complex pathophysiology 
and its relationship with platinum pharmacology remains elusive.27 This has hampered 
efforts to develop nephroprotective agents, which are therefore not yet in widespread 
use.27 Hence, it remains important to document the very long-term outcome of platinum 
nephrotoxicity and factors that determine its severity, to inform continued but safer use of 
these drugs, especially cisplatin. 
This prospective longitudinal single institution cohort study was based on 
evaluation of the commonest and most important components of platinum-induced 
glomerular and tubular toxicity, using measures that have been used in many previous 
studies.4,7,8,13,14,23,28,29 The grading score was designed to document and quantify 
clinically relevant nephrotoxicity.8 
Although considerable inter-individual variability in renal toxicity was seen in 
many survivors during the course of the study, manifest by marked improvement or 
deterioration in one or more aspects of nephrotoxicity, there was no significant change in 
the frequency and severity of overall nephrotoxicity during 10 years follow-up after 
treatment of children with cisplatin, carboplatin or both. In particular, there was no 
suggestion of deterioration in renal function with time. However, it is important to note 
that severe nephrotoxicity (ie Ns ≥4) appears to be lasting, being persistent in 15% of 
survivors 10 years after completion of cisplatin. Although chronic nephrotoxicity is well 
documented during the first three years after treatment completion, this is the first report 
of very long-term nephrotoxicity in children. Improved understanding of the nature and 
severity of long-term platinum nephrotoxicity is crucial to direct follow-up of current 
survivors and to facilitate the development of future platinum-containing protocols by 
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providing clearer information about the risks of severe or even life-threatening late 
toxicity. 
An important new finding of this study, which contrasts with the results of 
previous studies,8,13 is the importance of older age at treatment as a risk factor for 
cisplatin nephrotoxicity, both early (End) and late (10 years) after treatment completion. 
Although an early report suggested that higher cisplatin dose was correlated with greater 
acute nephrotoxicity in 28 adults,16 larger medium-term studies8,13 (in 35 and 40 children, 
respectively, studied at a median of about 2 years post-treatment) and this study have 
shown no relationship between cumulative cisplatin dose and chronic nephrotoxicity. 
However, this study confirms previous reports that high cisplatin dose rate may be more 
important as a risk factor for greater overall nephrotoxicity at 1 year, as evaluated by 
higher Ns.8,28,29 Although these findings should be confirmed in a larger patient 
population, it is feasible that they may allow continued use of this important 
chemotherapeutic agent with less concern about stringent restriction of cumulative dose. 
The limited published literature concerning carboplatin nephrotoxicity in children 
has suggested that higher cumulative dose is associated with greater tubular toxicity 
(manifest by lower Mg).7 This study has confirmed a correlation between higher 
cumulative carboplatin dose and increased tubular toxicity (lower Mg) at 1 year and 
greater overall nephrotoxicity at 1 and 10 years. A further and novel finding is that older 
age at treatment is correlated with greater glomerular toxicity (lower GFR) at all 
timepoints, tubular toxicity (lower Mg) at End and overall nephrotoxicity (Ns) at End and 
1 year. 
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Although previous studies have not suggested that potentially nephrotoxic 
supportive drugs used in children with malignancy (eg aminoglycosides, amphotericin) 
are risk factors in terms of the overall frequency of platinum-induced nephrotoxicity,8 it 
remains possible that they may be important factors in the development of renal damage 
in some individual survivors. 
This study has provided the longest follow-up of long-term platinum 
nephrotoxicity in children, but since the number of patients in each group was still 
relatively small, the findings require confirmation in larger studies. Nevertheless, despite 
the well-known difficulties of long-term follow-up research, the study included 93% of a 
single institution cohort of 10 year survivors. The findings are consistent with but extend 
considerably the previous experience with shorter follow-up. Although age-related 
variability in reference ranges may have limited the study’s ability to detect changes in 
renal function, this likelihood was reduced by the categorisation of results as normal or 
abnormal. 
In conclusion, platinum-induced nephrotoxicity persisted during 10 years follow-
up. An important new finding is that older age at treatment appears to be the major risk 
factor for nephrotoxicity, especially in carboplatin survivors, whilst higher cisplatin dose 
rate and cumulative carboplatin dose were also important predictors of some aspects of 
toxicity. The lack of late deterioration in renal function is reassuring and supports 
continued use of platinum chemotherapy in sensitive malignancies. However, further 
studies are required to evaluate very long-term renal function in view of the continued 
presence of severe toxicity at 10 years in 15% of cisplatin survivors, and to evaluate 
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potentially modifiable risk factors that may allow future reduction of the prevalence of 
severe and potentially life-shortening chronic platinum-induced nephrotoxicity. 
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TABLE 1 PATIENT AND TREATMENT CHARACTERISTICS 
 
 Cisplatin alone Carboplatin alone Cisplatin and 
carboplatin 
Number of 
patients (males) 
27 (11 males) 24 (14 males) 12 (9 males) 
Age at 
treatment 
commencement 
(yrs) 
7.7 (0.6-17.8) 4.4 (0.4-15.8) 1.9 (0.1-6.2) 
Total dose 
(mg/m2) 
500 (300-960) 2400 (560-8800) Cisplatin 473 (240-739) 
Carboplatin 1500 (750-4200) 
Diagnoses Osteosarcoma 
Germ cell tumour 
Brain tumour 
Liver tumour 
Epithelial carcinoma 
Ewing’s sarcoma 
Nasophayrngeal 
  carcinoma 
Neuroblastoma 
Salivary gland 
  carcinoma 
12 
4 
3 
3 
1 
1 
1 
 
1 
1 
Germ cell tumour 
Medulloblastoma 
Other brain 
  tumour 
Neuroblastoma 
CCSK 
Retinoblastoma 
9 
5 
5 
 
3 
1 
1 
Neuroblastoma 
Brain tumour 
9 
3 
Age and dose expressed as median (range) 
CCSK = clear cell sarcoma of kidney 
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TABLE 2 GRADING OF CISPLATIN NEPHROTOXICITY IN CHILDREN 8 
 
Nephrotoxicity 
Grade 
GFR Mg 
<2 years ≥2 years 
0 ≥90 ≥0.75 ≥0.70 
1 60-89 0.60-0.74 0.55-0.69 
2 40-59 0.50-0.59 0.45-0.54 
3 20-39 No symptoms, but 
0.40-0.49 0.35-0.44 
4 <20 Tetany or convulsion or 
<0.40 <0.35 
 
A score of 4 in an individual aspect of grading (eg GFR) constitutes severe toxicity 
in that aspect. 
Total nephrotoxicity score (Ns) = sum of GFR + Mg 
 0 No nephrotoxicity 
 1 Mild nephrotoxicity 
 2-3 Moderate nephrotoxicity 
 ≥4 Severe nephrotoxicity 
GFR =  glomerular filtration rate  (ml min-1 1.73m-2) 
Mg =  serum magnesium concentration  (mmol l-1) 
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TABLE 3 
RENAL FUNCTION INVESTIGATIONS AT END OF, ONE AND TEN YEARS AFTER PLATINUM TREATMENT 
 End of 
treatment 
 
One year after 
treatment 
 
Ten years after 
treatment 
 
Percentage of normal results 
End of 
treatment 
 
One year 
after 
treatment 
Ten years 
after 
treatment 
Cisplatin alone (n=20-22) (n=21-22) (n=26-27)    
GFR (ml/min/1.73m2) 84 (18-197) 98 (25-130) 96 (29-142) 40 (19-64) 62 (38-82) 60 (39-79) 
Serum Ca (mmol/l) 2.45 (2.02-2.60) 2.47 (2.19-2.66) 2.38 (2.18-2.53) 90 (70-99) 100 (87-100) 100 (89-100) 
Serum Mg (mmol/l) 0.68 (0.32-0.93) 0.70 (0.44-0.95) 0.73 (0.37-0.83) 48 (26-70) 50 (28-72) 68 (45-86) 
Nephrotoxicity score 1 (0-5) 1 (0-4) 1 (0-4) 57 (34-78) 64 (41-83) 63 (42-81) 
Carboplatin alone  (n=20-23) (n=21-23) (n=24)    
GFR (ml/min/1.73m2) 120 (68-207) 109 (63-161) 110 (66-171) 80 (56-94) 81 (58-95) 79 (58-93) 
Serum Ca (mmol/l) 2.42 (2.25-2.59) 2.48 (2.34-2.58) 2.39 (2.28-2.59) 100 (88-100) 100 (87-100) 100 (88-100) 
Serum Mg (mmol/l) 0.77 (0.42-0.89) 0.78 (0.51-0.90) 0.77 (0.54-0.94) 74 (52-90) 73 (50-89) 83 (61-95) 
Nephrotoxicity score 0 (0-4) 0 (0-2) 0 (0-2) 91 (71-99) 95 (77-100) 96 (79-100) 
Cisplatin and carboplatin (n=10-11) (n=12) (n=11-12)    
GFR (ml/min/1.73m2) 91 (45-160) 93 (55-131) 92 (66-135) 80 (44-97) 75 (43-95) 55 (23-83) 
Serum Ca (mmol/l) 2.39 (2.18-2.61) 2.46 (2.24-2.55) 2.36 (2.23-2.53) 100 (76-100) 100 (80-100) 100 (76-100) 
Serum Mg (mmol/l) 0.74 (0.62-0.98) 0.80 (0.68-0.89) 0.81 (0.68-0.92) 55 (23-83) 92 (62-100) 91 (59-100) 
Nephrotoxicity score 1 (0-3) 0 (0-2) 0 (0-2) 82 (48-98) 92 (62-100) 92 (62-100) 
 
 
Values of the renal function investigations are expressed as median (range). 
Percentage of patients with normal renal function investigations are expressed as percentage (95% confidence limits). 
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FIGURE 2 
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FIGURE LEGENDS 
 
FIGURE 1 
 
Renal function, measured by a) GFR and b) serum Mg at the end of, and 1 and 10 years 
after, cisplatin treatment. Joined lines show data from individual patients, and 
demonstrate considerable inter-patient variability in the severity of renal toxicity and in 
changes with time. 
 
FIGURE 2 
 
Scatter plots and regression lines showing relation between age at treatment with a) 
cisplatin and b) carboplatin, and GFR at 10 years after completion of treatment. Older age 
at treatment predicts lower GFR (p=0.005 for cisplatin, p=0.011 for carboplatin). 
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